A Long-Term Follow-Up Study Of Subjects Completing The AU-011-301(CoMpass) For Early Choroidal Melanoma

Overview

About this study

AU-011-403 is a multicenter long-term follow-up safety and efficacy study of subjects with early CM who previously participated in the AU-011-301 Phase 3 trial. There are no required interventions or use of AU-011 (bel-sar) in this long-term follow-up study

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

* Have received bel-sar or sham treatment in the Aura-sponsored clinical trial AU-011-301.
* Be willing and able to consent to the AU-011-403 study.

Exclusion Criteria:

* None

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 03/09/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Lauren Dalvin, M.D.

Open for enrollment

Contact information:

Suzanne Wernimont

5075388119

wernimont.suzanne@mayo.edu

More information

Publications

Publications are currently not available